Unrelated Donor Bone Marrow Transplantation for Myelodysplastic Syndrome in Children

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 5, 2011, Pages 723-728

  Woodard, Paul ^a   Carpenter, Paul A ^b   Davies, Stella M ^c   Gross, Thomas G ^d   He, Wensheng ^e   Zhang, Mei Jie ^e   Horn, Biljana N ^f   Margolis, David A ^g   Perentesis, John P ^c   Sanders, Jean E ^b   Schultz, Kirk R ^h   Seber, Adriana ⁱ   Woods, William G ^j   Eapen, Mary ^e  

^a AMGEN INC   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^d NATIONWIDE CHILDREN S HOSPITAL   (United States)

^e CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g Children's Hospital of Wisconsin   (United States)

^h BC CHILDREN S HOSPITAL   (Canada)

ⁱ Instituto de Oncologia Pediatrica   (Brazil)

^j AFLAC   (United States)

more..

Author keywords

Bone marrow transplantation; Pediatric myelodysplastic syndrome; Unrelated donor

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; MELPHALAN;

ADOLESCENT; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CHILD; CHILDHOOD DISEASE; CYTOPENIA; DISEASE FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOSOMY 7; MORTALITY; MYELODYSPLASTIC SYNDROME; NEUTROPHIL; ORGAN DONOR; PRESCHOOL CHILD; RECURRENT DISEASE; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; REFRACTORY CYTOPENIA; RISK FACTOR; SCHOOL CHILD; THROMBOCYTE; TREATMENT FAILURE; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ADOLESCENT; ANTINEOPLASTIC AGENTS; BLOOD PLATELETS; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HLA ANTIGENS; HUMANS; MALE; MYELODYSPLASTIC SYNDROMES; NEUTROPHILS; RECURRENCE; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT FAILURE;

EID: 79954608298     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.08.016     Document Type: Article

References (18)

1. Hasle H., Kerndrup G., Jacobsen B.B. Childhood myelodysplastic syndrome in Denmark: incidence and predisposing conditions. Leukemia 1995, 9:1569-1572.
2. Locatelli F., Pession A., Bonetti F., et al. Busulfan, cyclophosphamide and melphalan as conditioning regimen for bone marrow transplantation in children with myelodysplastic syndromes. Leukemia 1994, 8:844-849.
3. Woods W.G., Barnard D.R., Alonzo T.A., et al. Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukemia or myelodysplastic syndrome: a report from the Children's Cancer Group. J Clin Oncol 2002, 20:434-440.
4. Davies S.M., Wagner J.E., Defor T., et al. Unrelated donor bone marrow transplantation for children and adolescents with aplastic anaemia or myelodysplasia. Br J Haematol 1997, 96:749-756.
5. Yusuf U., Frangoul H.A., Gooley T.A., et al. Allogeneic bone marrow transplantation in children with myelodysplastic syndrome or juvenile myelomonocytic leukemia: the Seattle experience. Bone Marrow Transplant 2004, 33:805-814.
6. Deeg H.J., Storer B., Slattery J.T., et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 2002, 100:1201-1207.
7. Hasle H., Niemeyer C.M., Chessells J.M., et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia 2003, 17:277-282.
8. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on acute GVHD grading. Bone Marrow Transplant 1995, 15:825-828.
9. Atkinson K., Horowitz M.M., Gale R.P., et al. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood 1990, 75:2459-2464.
10. Lin D.Y. Non-parametric inference for cumulative incidence functions in competing risks studies. Stat Med 1997, 16:901-910.
11. Klein J., Moeschberger M. Survival Analysis: Techniques of Censored and Truncated Data 2003, Springer-Verlag, New York.
12. Cox D.R. Regression models and life tables. J R Stat Soc 1972, 34:187-202.
13. Lee S.J., Klein J., Haagenson M., et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007, 110:4576-4583.
14. Kroger N., Zabelina T., Kruger W., et al. Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients. Bone Marrow Transplant 2001, 27:349-354.
15. Ringden O., Remberger M., Ruutu T., et al. Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplantation Group. Blood 1999, 93:2196-2201.
16. Strahm B., Locatelli F., Bader P., et al. Reduced intensity conditioning in unrelated donor transplantation for refractory cytopenia in childhood. Bone Marrow Transplant 2007, 40:329-333.
17. Parikh S.H., Mendizabal A., Martin P.L., et al. Unrelated donor umbilical cord blood transplantation in pediatric myelodysplastic syndrome: a single-center experience. Biol Blood Marrow Transplant 2009, 15:948-955.
18. MorenoMadureira A.B., Teira P., Locatelli F., et al. Risk factors analyses for outcomes after unrelated cord blood transplantation for children with myelodysplastic syndromes. An analysis on behalf of EWOG-MDS and Eurocord Groups. Blood 2007, 118:602a.